Definium Therapeutics Surges 60% on Breakthrough Depression Drug Data

Definium Therapeutics Inc. shares surged as much as 60% on Monday after the company announced groundbreaking late-stage trial results for its experimental psychedelic-based treatment for major depressive disorder.

The rally came after Definium reported that its drug, a synthetic psychedelic compound, met all primary and secondary endpoints in a Phase 3 trial, showing statistically significant improvement in depression scores compared to placebo. The company described the data as "groundbreaking" and plans to file for regulatory approval later this year. The stock closed up 55% on heavy volume, making it one of the top gainers in the biotech sector.

For equity traders, the surge highlights the growing investor appetite for psychedelic drug developers, a niche that has seen increased attention as regulatory attitudes shift. Definium's success could also lift sentiment for other companies in the space, such as Compass Pathways and MindMed, which have similar drug candidates in development. Traders can track real-time price movements of Definium and its peers on NowPrice's live stocks dashboard to monitor sector momentum.

Looking ahead, investors will focus on Definium's regulatory submission timeline and potential partnership announcements. The company is expected to meet with the FDA in the coming months to discuss the approval pathway. If approved, the drug could become a major player in the $15 billion depression treatment market, but risks remain regarding safety data and manufacturing scale-up.